» Articles » PMID: 7975859

Long-lasting Protection of Sheep Against Bluetongue Challenge After Vaccination with Virus-like Particles: Evidence for Homologous and Partial Heterologous Protection

Overview
Journal Vaccine
Date 1994 Jul 1
PMID 7975859
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

Insect cells co-infected with appropriate recombinant baculoviruses synthesize double-shelled, virus-like particles (VLPs) with bluetongue virus (BTV) VP2 proteins representing serotype 1 (BTV-1), 2 (BTV-2), 10 (BTV-10), 13 (BTV-13) or 17 (BTV-17) as previously reported for BTV-10 (French, T.J., Marshall, J.J.A. and Roy, P. J. Virol. 1990, 64, 5696-5700). The derived particles were purified and used to vaccine sheep, either as single VLP types (BTV-10, BTV-17) or as a combination of all five serotypes. Control sheep received saline. The virus-neutralizing antibody responses were measured. Depending on the experiment, the sheep were challenged with homologous (BTV-10, -13, -17) or selected heterologous (BTV-4, -11, -16) viruses either after 4 months or 14 months, and the disease, viraemias and clinical reactions monitored. The results indicated that two doses of 10 micrograms of VLPs elicited a long-lasting immune response which protected the sheep against challenge with the homologous virulent virus. In certain cases, partial protection was afforded against challenge by heterologous BTV serotypes.

Citing Articles

Impact of VP2 structure on antigenicity: comparison of BTV1 and the highly virulent BTV8 serotype.

Bissett S, Roy P J Virol. 2024; 98(10):e0095324.

PMID: 39320096 PMC: 11494903. DOI: 10.1128/jvi.00953-24.


Multi-Gene Recombinant Baculovirus Expression Systems: From Inception to Contemporary Applications.

Bissett S, Roy P Viruses. 2024; 16(4).

PMID: 38675835 PMC: 11054102. DOI: 10.3390/v16040492.


Specific T-cell subsets have a role in anti-viral immunity and pathogenesis but not viral dynamics or onwards vector transmission of an important livestock arbovirus.

Newbrook K, Khan N, Fisher A, Chong K, Gubbins S, Davies W Front Immunol. 2024; 15:1328820.

PMID: 38357545 PMC: 10864546. DOI: 10.3389/fimmu.2024.1328820.


Nanoadjuvants: Promising Bioinspired and Biomimetic Approaches in Vaccine Innovation.

Desai D, Mahal A, Varshney R, Obaidullah A, Gupta B, Mohanty P ACS Omega. 2023; 8(31):27953-27968.

PMID: 37576639 PMC: 10413842. DOI: 10.1021/acsomega.3c02030.


Increased Clinical Signs and Mortality in IFNAR Mice Immunised with the Bluetongue Virus Outer-Capsid Proteins VP2 or VP5, after Challenge with an Attenuated Heterologous Serotype.

Attoui H, Mohd Jaafar F, Monsion B, Klonjkowski B, Reid E, Fay P Pathogens. 2023; 12(4).

PMID: 37111488 PMC: 10141489. DOI: 10.3390/pathogens12040602.